Literature DB >> 12650706

Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.

Ping Zhan1, Edmund Chun Yu Lee, Kathryn Packman, Martin Tenniswood.   

Abstract

The cellular mechanisms of anti-androgen-induced tumor regression have not been investigated in great detail. We have compared the induction of cell death in the androgen-dependent, non-invasive LNCaP prostate cancer cell line by Casodex and TNF-alpha. Both agents induce a dose and time-dependent decrease in cell viability in vitro. However, Casodex does not induce classical DNA fragmentation to oligonucleosomes typically induced by TNF-alpha, but rather induces cleavage to form intermediate 60 kb DNA fragments. RT-PCR based analysis demonstrates that in LNCaP cells Casodex coordinately alters the expression of steady-state level of mRNAs of several matrix metalloproteases and their cognate inhibitors (most notably MMP2 and TIMP1). Zymography and reverse zymography confirm that the ratio of metalloprotease(s) to inhibitor(s) is altered in favor of activation of the proteases. In a small percentage of the treated LNCaP cells, the activation of the extracellular matrix (ECM)-proteases by Casodex also induces an invasive phenotype. The acquisition of an invasive phenotype is not seen when LNCaP cells are treated with TNF-alpha, and is not seen when the LNCaP cells are treated with both compounds simultaneously, suggesting that the phenomenon may be specific to particular classes of compounds. These observations have significant implications in the treatment of prostate cancer, since the appearance of a more aggressive phenotype following treatment is clearly undesirable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12650706     DOI: 10.1016/s0960-0760(02)00275-3

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Androgen receptor interacts with telomeric proteins in prostate cancer cells.

Authors:  Sahn-Ho Kim; Michelle Richardson; Kannagi Chinnakannu; V Uma Bai; Mani Menon; Evelyn R Barrack; G Prem-Veer Reddy
Journal:  J Biol Chem       Date:  2010-01-28       Impact factor: 5.157

2.  Effects of clusterin over-expression on metastatic progression and therapy in breast cancer.

Authors:  Louise Flanagan; Lorna Whyte; Namita Chatterjee; Martin Tenniswood
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

3.  ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.

Authors:  Vidyavathi Reddy; Min Wu; Nicholas Ciavattone; Nathan McKenty; Mani Menon; Evelyn R Barrack; G Prem-Veer Reddy; Sahn-Ho Kim
Journal:  J Biol Chem       Date:  2015-09-02       Impact factor: 5.157

4.  Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase.

Authors:  Shalini Murthy; Min Wu; V Uma Bai; Zizheng Hou; Mani Menon; Evelyn R Barrack; Sahn-Ho Kim; G Prem-Veer Reddy
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

5.  Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival.

Authors:  Qing Yang; Kar-Ming Fung; Wanda V Day; Bradley P Kropp; Hsueh-Kung Lin
Journal:  Cancer Cell Int       Date:  2005-04-06       Impact factor: 5.722

6.  Structural and functional association of androgen receptor with telomeres in prostate cancer cells.

Authors:  Junying Zhou; Michelle Richardson; Vidyavathi Reddy; Mani Menon; Evelyn R Barrack; G Prem-Veer Reddy; Sahn-Ho Kim
Journal:  Aging (Albany NY)       Date:  2013-01       Impact factor: 5.682

7.  Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.

Authors:  N M Byrne; H Nesbitt; L Ming; S R McKeown; J Worthington; D J McKenna
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.